March 12, 2026

 

Zenex Animal Health acquires VievePharm to accelerate EU natural alternatives push

 

With the European Union's Farm-to-Fork Strategy requiring a 50% cut in veterinary antibiotic sales by 2030, demand for science-backed natural alternatives is accelerating across European livestock markets.

 

Zenex Animal Health India Private Limited has positioned itself at the centre of that shift, acquiring a majority stake in VievePharm, a Netherlands-based specialist in phytogenic animal nutrition.

 

The transaction brings Zenex a GMP+-certified Dutch manufacturing facility, an established distribution network across more than 25 countries, and deep expertise in bolus delivery technology - a precision format for mineral, vitamin, and udder health supplementation in livestock.

 

Financial terms were not disclosed.

 

For VievePharm, the deal provides the global reach and R&D resources to scale its "Best of Nature" phytogenic formulations across European markets and beyond.

 

The strategic rationale of the transaction entails three pillars:

 

    - Strengthening the naturals portfolio: VievePharm's phytogenic expertise builds directly on Zenex's herbal and Ayurvedic range, including capabilities acquired through the 2023 purchase of Ayurvet. The combined portfolio is positioned to benefit directly from the EU's antibiotic reduction mandate, as farmers seek proven natural productivity tools;

 

    - Advanced bolus manufacturing. VievePharm's Dutch facility is GMP+, FSA, and Skal certified, providing Zenex with specialist delivery technology for precision nutritional supplementation. This capability will be deployed to enhance Zenex's product offering across its global markets;

 

    - Western European presence and export growth: Zenex currently operates across Asia, Africa, and the CIS region. VievePharm's established EU distribution network - serving more than 60 customers across more than 25 countries – gives Zenex a platform to launch its broader therapeutic and nutritional range into Western European markets for the first time.

 

Dr. Arun Atrey, managing director and chief executive officer of Zenex Animal Health, said: "The acquisition of VievePharm is a logical progression of our first-principles approach to animal healthcare, focusing on prevention and sustainable productivity. By combining VievePharm's advanced bolus technology and European market access with our R&D depth and global distribution, we are positioned to offer holistic, science-backed solutions that address the root causes of animal health challenges."

 

Renuka Ramnath, chairperson of Zenex, as well as founder, MD and CEO of Multiples, said: "We are excited about the combination with VievePharm, as it strengthens Zenex's ability to provide science-backed, herbal alternatives to markets that are increasingly favouring natural products. Strategic acquisitions that provide important capability additions, like VievePharm's bolus technology and European footprint, will continue to be a vital part of the value creation journey at Zenex as we scale our leadership globally."

 

Arie Boorsma, founder of VievePharm, said: "Joining forces with Zenex allows us to scale our "Best of Nature" philosophy to a global stage. Our commitment to sustainable livestock farming and innovation in animal nutrition aligns perfectly with Zenex's vision. This partnership will provide the resources and reach necessary to deepen our operations in the Netherlands and take our solutions to farmers across Europe and broader international markets."

 

Zenex Animal Health is one of India's largest animal health companies. Boasting a legacy of over 60 years, Zenex has built an extensive distribution network with more than 1,200 sales employees in India and serves customers across more than 15 countries in the Middle East, Africa, Eastern Europe, and Southeast Asia.

 

Backed by a consortium of investors led by Multiples PE, Zenex provides a comprehensive range of animal health products spanning therapeutics, vaccines, and herbal solutions for livestock, poultry, and companion animals.

 

Based in Enter, Netherlands, VievePharm is a specialist in natural animal nutrition. The company develops and produces high-quality boluses, supplements, and private-label products designed to improve animal resilience and reduce reliance on antibiotics.

 

Founded in 2006, VievePharm serves customers in the livestock, equine, and pet care markets.

 

- Investec Advisory